These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33502252)

  • 1. Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer.
    Li Y; Chen X; Zhu Q; Chen R; Xu L; Li S; Shi X; Xu H; Xu Y; Zhang W; Huang X; Zha X; Wang J
    Nanomedicine (Lond); 2021 Feb; 16(5):391-400. PubMed ID: 33502252
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.
    Xie F; Chen R; Zhang L; Yin Z; Zhu Q; You S; Jiang C; Li Y; Li S; Zha X; Wang J
    Nanomedicine (Lond); 2019 Jun; 14(12):1595-1603. PubMed ID: 30977429
    [No Abstract]   [Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
    Shi W; Wan X; Wang Y; He J; Huang X; Xu Y; Zhang W; Chen R; Wang L; Zheng R; Ma L; Li X; Xu L; Zha X; Wang J
    Nanomedicine; 2023 Apr; 49():102666. PubMed ID: 36889422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.
    Zhang W; Xu Y; Shi X; Huang X; Chen R; Xu H; Shi W; Wan X; Wang Y; He J; Li C; Wang J; Zha X
    Nanomedicine (Lond); 2022 Apr; 17(10):683-694. PubMed ID: 35393861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
    Zhang W; Wang Y; He J; Xu Y; Chen R; Wan X; Shi W; Huang X; Xu L; Wang J; Zha X
    Nanomedicine; 2023 Nov; 54():102707. PubMed ID: 37717927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
    Shizuku M; Shibata M; Shimizu Y; Takeuchi D; Mizuno Y
    Nagoya J Med Sci; 2020 Aug; 82(3):457-467. PubMed ID: 33132430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer.
    Matsumoto A; Jinno H; Naruse S; Isono Y; Maeda Y; Sato A; Yamada M; Ikeda T; Sasajima Y
    Jpn J Clin Oncol; 2023 Dec; 53(12):1119-1124. PubMed ID: 37609671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
    Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
    Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
    Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K
    Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients].
    Kang Y; Shiraki E; Tsuyuki S
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1427-1431. PubMed ID: 31530783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Lv ZD; Song HM; Niu ZH; Nie G; Zheng S; Xu YY; Gong W; Wang HB
    Front Oncol; 2021; 11():760655. PubMed ID: 35087749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.
    Yang M; Qu H; Liu A; Liu J; Sun P; Li H
    J Cancer Res Ther; 2019; 15(7):1561-1566. PubMed ID: 31939438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
    Su W; Zhang S; Li C; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):379-82. PubMed ID: 26463031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
    Li WP; Zhu T; Hu MX; Yang M; Ji F; Gao HF; Yang CQ; Zhang LL; Cheng MY; Xu FP; Wang K
    Neoplasma; 2020 Nov; 67(6):1409-1415. PubMed ID: 32657611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.